Charles River’s range of translational tools for neuroscience drug discovery enable deeper scientific knowledge and technical collaboration, enhancing the overall scientific understanding of your compound. In vivo pharmacology and early safety and efficacy testing benefit early-stage discovery research, and can be utilized to further understand your novel drug candidate targeting any neurological indication. Our neuroscience toolkit encompasses biomarker development, pathology, behavioral and cognitive testing, physiology, and state-of-the-art imaging methods. Robust preclinical testing in rodent and non-rodent models, combined with comprehensive pathology services and market-leading cardiac risk assessment services, helps shorten the time required to move a promising lead compound into the clinic.